Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms - Wikidata - awgldk - TriplyDB

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

http://www.wikidata.org/entity/Q24629306

about

Comprehensive molecular portraits of human breast tumours Genomic landscape of megakaryopoiesis and platelet function defects Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management Defects in spliceosomal machinery: a new pathway of leukaemogenesis Misregulation of pre-mRNA alternative splicing in cancer SF3B1 mutations in chronic lymphocytic leukemia.Aberrant splicing and drug resistance in AML Refractory anemia with ring sideroblasts and RARS with thrombocytosis MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts.Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.[Myelodysplastic syndromes].Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.Molecular Testing in Patients with Suspected Myelodysplastic Syndromes.Clinical and genetic predictors of prognosis in myelodysplastic syndromes.The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers.Genetic characterization of SF3B1 mutations in single chronic lymphocytic leukemia cells The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure Tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome.Muscleblind-like 1 (Mbnl1) regulates pre-mRNA alternative splicing during terminal erythropoiesis Aberrant RNA splicing and mutations in spliceosome complex in acute myeloid leukemia.Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease.Limiting of the innate immune response by SF3A-dependent control of MyD88 alternative mRNA splicing.Myelodysplasia is in the niche: novel concepts and emerging therapies.Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome.Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies.Regulation of toll-like receptor signaling by the SF3a mRNA splicing complex.Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells Deregulation of genes related to iron and mitochondrial metabolism in refractory anemia with ring sideroblasts The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets.Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia.Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes Jerantinine A induces tumor-specific cell death through modulation of splicing factor 3b subunit 1 (SF3B1)

P2860

Q24630844-D7AC15E8-E209-453E-9AD9-56891A3F6125 Q26770869-9EF16761-F2D7-49F6-A208-1908AD384470 Q26796240-E53F279E-ED1D-4C19-93B8-34453BBFC634 Q26823040-3C88DEF6-51FD-4B2D-9313-753002887193 Q27007114-5A7AE7D2-1702-4766-A843-556DDD76BA4D Q27852162-F5A91434-831B-437E-AAEB-A201BF90140B Q28076011-3B7EE66A-295C-4602-B049-A744774C3B1F Q28083238-E9A132D2-8AAB-4AB4-B823-B8D1AD5B3FC1 Q28394317-1C61E80A-AD8B-44AA-A41F-240F49A4682B Q30235355-74B14E79-5E24-4E74-8E2A-F5DDE5752281 Q30249108-FBCA97DA-92E3-461F-9F36-19FDFBCFAD0D Q30883788-C36F13A3-2C90-4D13-B37F-393074BD2ECA Q33420574-E7B5D405-C2D0-4649-B8A4-0593C6B05726 Q33427165-341216D2-C370-449C-BE41-8304FC3D9AF1 Q33435980-C486C847-68C8-4921-A57F-A2339675DE3E Q33695906-5D206A70-A365-4D93-AE51-9D398F82B970 Q33746465-8B82C539-1E29-4449-A4BA-4EFD286BBD6A Q33767762-19BE4E6F-C92F-4B95-B6BD-29E83382E2DA Q33828825-2A211BAA-2262-4AEE-861C-31C7E00834BF Q33829778-403A9B4C-4D74-47CC-A331-FF43A5EDC7D1 Q33945004-481515C3-0021-4962-A1CA-B8CF289A44B7 Q33948731-49C2AF35-9E01-46F5-9472-9E326CA3235E Q34047994-E205C3FD-F159-4FC3-AA6A-4DD8A07D0977 Q34106883-2BEBB494-EE10-4B90-88FC-44001E4D715C Q34667249-61D858A9-BCBF-48E6-A435-91B40E987293 Q35034303-94AD1FB8-5A27-4A35-87BE-A69B66914EAB Q35059425-EC16655A-6136-4AA3-9EB3-CBD1AECF2EC5 Q35148150-7B0087F2-887F-40A9-B5AA-737B266DA8F1 Q35538419-D07CFFF1-0963-4922-A633-4398F6E1804B Q35556982-D7359A0C-5B92-4891-9F7C-8BAD9EFA8644 Q35603613-703DAEA5-3C24-41B1-B52F-9C5E3CBED4CC Q35625385-CB29D556-95CD-45C9-B209-88298CFB4618 Q35675958-4C5B5849-E7C8-400C-8539-49AF8DC91FC1 Q35690609-86E2F825-6EE2-448D-9AA4-3817552F6EE2 Q35713371-59E7B3A1-BBDD-4AC2-B775-DD5F221591B9 Q35743810-38BF0CEC-F0F0-4680-9247-9DD0A4356F5A Q35876928-03B348DC-2778-4BFE-B605-F10B7FE8D653 Q35925679-FA23FF4D-1F2D-43C6-AB0D-D53D8044C11F Q36222935-27A700E9-8DB3-48A2-B4FA-1642C31FFB62 Q36280761-AB1CB58A-D61E-46B7-9E07-998E38B17B13

P2860

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

http://www.wikidata.org/entity/Q24629306

description

2011 nî lūn-bûn

@nan

2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Clinical significance of SF3B1 ...... c/myeloproliferative neoplasms

@ast

Clinical significance of SF3B1 ...... c/myeloproliferative neoplasms

@en

Clinical significance of SF3B1 ...... c/myeloproliferative neoplasms

@nl

type

label

Clinical significance of SF3B1 ...... c/myeloproliferative neoplasms

@ast

Clinical significance of SF3B1 ...... c/myeloproliferative neoplasms

@en

Clinical significance of SF3B1 ...... c/myeloproliferative neoplasms

@nl

prefLabel

Clinical significance of SF3B1 ...... c/myeloproliferative neoplasms

@ast

Clinical significance of SF3B1 ...... c/myeloproliferative neoplasms

@en

Clinical significance of SF3B1 ...... c/myeloproliferative neoplasms

@nl

P1433

Q24629306-7AE60C16-4C90-4132-A14F-77A1E1D093D8

P1476

Q24629306-21850CA6-C562-4C42-8B45-7C084A1EAC5E

P2093

Q24629306-0B0DA127-659A-4D82-A4F1-FAF3FC6DFEBD

Q24629306-0DA90639-531C-4062-B1E2-5FC5B5AB258B

Q24629306-2F447CD9-B2A0-47C0-B209-B76F9AB074F6

Q24629306-3AB647BD-53AB-45F2-9E5F-96998D00B903

Q24629306-69C3F28E-574F-448B-ADC3-371054F65CBC

Q24629306-7F35A818-EE34-4324-9BD0-5D0A822684DF

Q24629306-8AF79646-6A73-428B-AFC3-384B453A1798

Q24629306-98B0FBC8-32CD-457A-AC2C-50C82823CE07

Q24629306-A3A76D72-2FA2-4D7B-9BC0-94B38E675692

Q24629306-AA8A837E-A137-4684-A172-09762691C08E

P2860

Q24629306-1E8C2C33-4481-4327-B3DA-C8F83A7E08FE

Q24629306-21B029B7-685B-4B7E-869A-32152EFD5016

Q24629306-2C967537-877D-4DDC-92E7-D66B5C4DE5C2

Q24629306-30D2D4E3-7506-434E-9388-55D463F6FFFB

Q24629306-34D243FC-DF84-4D8A-BFEF-33A4AFCE19E1

Q24629306-527CADDC-110F-44CB-AD34-8426C45C8B9A

Q24629306-53D478C1-72F2-4B33-A6FB-0DDF4D90F2C6

Q24629306-57B5FDC1-4EC2-4392-84BB-DBB1536FADCB

Q24629306-5A01CCB7-4C29-4D4D-BF0C-FF1E77CAE114

Q24629306-5BCF788E-3835-41FB-BA8D-C52DFAE3ACD0

P304

Q24629306-7CA7244B-2D0A-4E8A-A3A4-CE62D47083F2

P31

Q24629306-DEB5FD26-DDB8-48D7-AAE0-54597DC8C1B1

P3181

Q24629306-247753A7-8C66-4FAB-8AC0-048E03585C8A

P356

Q24629306-214C74DA-C513-43B2-AB00-D7B7FEBA0A37

P407

Q24629306-67F961BB-2210-441A-A30E-10F7196677E5

P433

Q24629306-47F70704-66B2-4DA7-ADA3-43486D43FACD

P478

Q24629306-969091B3-A0C9-4FC4-A238-FEBA12DB123A

P50

Q24629306-1F707241-873B-4213-B3A2-CC71FD7A1A45

Q24629306-22964A62-F10B-440F-9A67-1BA2EAB73DCB

Q24629306-2AFBFE74-FFDA-453E-A7C8-C82820CCBE0A

Q24629306-90885F8C-9032-4E2E-B43E-CDBA04848462

Q24629306-CB30CEFA-5694-4274-BBC5-9BAF0D4D31B4

P577

Q24629306-2BE7585B-3604-40C4-8B6B-2CAF77D1739C

P5875

Q24629306-F8554BA3-12A8-4EBD-9B94-A3665A942B57

P698

Q24629306-6E50BA84-0023-4759-97C1-E687675CBA0F

P921

Q24629306-4AC635D2-B386-4FC3-BD54-C6717846B9CD

P932

Q24629306-4FAE77CC-B0F8-4069-A0C9-A6D4166C2B7C

P3181

P356

BLOOD-2011-09-377275

P1433

P1476

Clinical significance of SF3B1 ...... c/myeloproliferative neoplasms

@en

P2093

Ann Hyslop

http://www.w3.org/2001/XMLSchema#string

Anna Gallì

http://www.w3.org/2001/XMLSchema#string

Anna L Godfrey

http://www.w3.org/2001/XMLSchema#string

Cristiana Pascutto

http://www.w3.org/2001/XMLSchema#string

David T Bowen

http://www.w3.org/2001/XMLSchema#string

Erica Travaglino

http://www.w3.org/2001/XMLSchema#string

Eva Hellström-Lindberg

http://www.w3.org/2001/XMLSchema#string

Ilaria Ambaglio

http://www.w3.org/2001/XMLSchema#string

James S Wainscoat

http://www.w3.org/2001/XMLSchema#string

Jonathan Hinton

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts

The World Health Organization (WHO) classification of the myeloid neoplasms

Myelodysplastic/myeloproliferative neoplasms

Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts

International scoring system for evaluating prognosis in myelodysplastic syndromes

Frequent pathway mutations of splicing machinery in myelodysplasia

Mutation in TET2 in myeloid cancers

P304

6239-46

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3405044

http://www.w3.org/2001/XMLSchema#string

P356

10.1182/BLOOD-2011-09-377275

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Jacqueline Boultwood

Eva Hellström-Lindberg

Elli Papaemmanuil

P Andrew Futreal

Michael Stratton

P577

2011-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51716169

http://www.w3.org/2001/XMLSchema#string

P698

21998214

http://www.w3.org/2001/XMLSchema#string

P921

P932

3236114

http://www.w3.org/2001/XMLSchema#string